BCL9 and neoplasm: In this work, CM-CA not only achieves the goal of disrupting intracellular β-catenin/BCL9 interaction in tumor cells, addressing the endogenous cause of insufficient immune infiltration, but also may function as a reservoir of tumor-associated antigens owing to its tumor cell mimicking properties, eliciting a heightened anti-tumor immune response (66).